At Cumberland, we’re always seeking opportunities to maximize the potential of our existing brands, develop new ways to use our products, expand our roster of distinguished partners and acquire select new brands. We're pleased to share several notable developments on this front from the first quarter of 2022:
Also during the first quarter, we shared several developments regarding Vibativ®, our antibiotic used to treat patients with pneumonia and serious skin infections resulting from gram positive bacteria:
I’d like to extend a big thank you to our team at Cumberland for their continued support of our mission to provide high-quality medical care to patients throughout the world. We’re particularly encouraged by our acquisition of Sancuso and our new national co-promotion partnership with Verity Pharmaceuticals. With the contributions from the new product, we expect to deliver double-digit revenue growth this year while continuing to generate positive cashflow from operations.
We look forward to sharing more updates with you throughout the year.